Abstract
Asian and western countries differ in the prevalence, symptom manifestation, diagnostic procedures, patient recognition and treatments of major depressive disorder (MDD), according to a number of studies. Ethnic differences in pharmacological profiles are also important in the prescription of certain antipsychotic medications because they may impact treatment outcomes and adverse events. Differential pharmacokinetic and pharmacodynamic properties of antipsychotics may be practically useful in the control of specific depressive symptoms. Furthermore, patient compliance with prescribed medications has been found to be different across races and ethnicities. Therefore, this article explores practical clinical issues for the use of atypical antipsychotics in patients with MDD, focusing on ethno-cultural differences.
| Original language | English |
|---|---|
| Pages (from-to) | S47-S51 |
| Journal | CNS Drugs |
| Volume | 27 |
| Issue number | SUPPL.1 |
| DOIs | |
| Publication status | Published - 2013 May |
| Externally published | Yes |
Bibliographical note
Funding Information:Conflict of interest Dr Han has received research grants from GlaxoSmithKline Korea, Eisai Korea, Korea Otsuka International Asia and Arab, Hanlim Pharmaceutical, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, Korean Research Foundation, and Otsuka Korea; and has received honoraria from GlaxoSmithKline Korea, Lundbeck Korea, Astra-Zeneca Korea, Janssen Pharmaceuticals Korea, Eisai Korea, Abott Korea, Eli Lilly and Company Korea, Norvatis Korea and Otsuka Korea. Dr Pae has received research grants from Eisai Korea, Janssen Pharmaceuticals Korea, Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea, and Korean Research Foundation; and has received honoraria from Pfizer Korea and Otsuka Korea.
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
